Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MAAQ NASDAQ:MURA NASDAQ:MYNZ NASDAQ:SNYR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMAAQMana Capital Acquisition$3.50-4.6%$3.93$5.35▼$10.25$28.44MN/A33,075 shs29,645 shsMURAMural Oncology$2.07-1.0%$2.27$0.95▼$4.74$36.21M3489,667 shs1.31 million shsMYNZMainz Biomed$1.76+2.3%$1.66$1.30▼$18.40$7.87M0.25176,773 shs69,868 shsSNYRSynergy CHC$2.90+1.4%$3.22$1.19▼$10.00$26.96MN/A51,274 shs31,014 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMAAQMana Capital Acquisition-1.34%-1.87%-14.65%-15.24%+715.56%MURAMural Oncology+16.11%+16.76%-15.73%-24.00%-35.09%MYNZMainz Biomed-4.44%0.00%-19.25%-18.10%-88.73%SNYRSynergy CHC-12.80%-25.91%-18.29%+40.20%+9,433.33%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMAAQMana Capital AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AMURAMural Oncology2.9653 of 5 stars3.33.00.00.01.82.51.3MYNZMainz Biomed2.4776 of 5 stars3.33.00.00.01.70.81.3SNYRSynergy CHC4.349 of 5 stars3.80.00.00.02.93.33.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMAAQMana Capital Acquisition 0.00N/AN/AN/AMURAMural Oncology 2.50Moderate Buy$12.00479.71% UpsideMYNZMainz Biomed 2.50Moderate Buy$14.00695.45% UpsideSNYRSynergy CHC 3.50Strong Buy$10.00244.83% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMAAQMana Capital AcquisitionN/AN/AN/AN/AN/AN/AMURAMural OncologyN/AN/AN/AN/A$3.39 per shareN/AMYNZMainz Biomed$890K9.06N/AN/A$2.61 per share0.67SNYRSynergy CHC$34.83M0.79$0.27 per share10.73($1.31) per share-2.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMAAQMana Capital AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/AMURAMural Oncology-$128.51M-$8.59N/AN/AN/AN/A-107.76%-87.57%N/AMYNZMainz Biomed-$21.65M-$65.60N/AN/AN/AN/AN/AN/AN/ASNYRSynergy CHC$2.12M$0.387.634.92N/A10.02%-18.56%20.28%N/ALatest MYNZ, SNYR, MURA, and MAAQ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025SNYRSynergy CHC$0.08$0.17+$0.09$0.17$10.80 million$6.74 million8/4/2025Q2 2025MURAMural Oncology-$1.13-$1.77-$0.64-$2.78N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMAAQMana Capital AcquisitionN/AN/AN/AN/AN/AMURAMural OncologyN/AN/AN/AN/AN/AMYNZMainz BiomedN/AN/AN/AN/AN/ASNYRSynergy CHCN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMAAQMana Capital AcquisitionN/AN/AN/AMURAMural OncologyN/A2.872.87MYNZMainz Biomed0.141.321.26SNYRSynergy CHCN/A2.741.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMAAQMana Capital Acquisition68.44%MURAMural Oncology80.21%MYNZMainz BiomedN/ASNYRSynergy CHCN/AInsider OwnershipCompanyInsider OwnershipMAAQMana Capital AcquisitionN/AMURAMural Oncology2.20%MYNZMainz Biomed18.20%SNYRSynergy CHC56.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMAAQMana Capital Acquisition18.13 millionN/ANot OptionableMURAMural Oncology11917.32 million16.94 millionOptionableMYNZMainz Biomed304.58 million3.75 millionNot OptionableSNYRSynergy CHC409.44 million4.10 millionN/AMYNZ, SNYR, MURA, and MAAQ HeadlinesRecent News About These CompaniesSynergy CHC Corp to Present at the 2025 Gateway Conference on September 4thAugust 21 at 9:40 AM | markets.businessinsider.comNew to The Street’s Esteemed Client Synergy CHC Corp. (NASDAQ: SNYR) Announces Nationwide EG America Rollout for FOCUSfactor(R) Focus + Energy EG America, 6th Largest U.S ...August 20 at 6:38 PM | palmbeachpost.comPSynergy CHC Corp. (NASDAQ: SNYR) Announces Nationwide EG America Rollout for FOCUSfactor® Focus + EnergyAugust 18 at 1:09 PM | taiwannews.com.twTNew to The Street's Esteemed Client Synergy CHC Corp. Announces Nationwide EG America Rollout for FOCUSfactor Focus + Energy EG America, 6th Largest U.S. Convenience Chain ...August 18 at 1:09 PM | finanznachrichten.deSynergy CHC announces major distribution with for FOCUSfactor Focus + EnergyAugust 18 at 1:09 PM | msn.comSynergy CHC Expands FOCUSfactor Distribution with EG AmericaAugust 18 at 9:59 AM | tipranks.comAnalysts Set Expectations for Synergy CHC FY2025 EarningsAugust 18 at 3:01 AM | americanbankingnews.comSynergy CHC files to sell 1.28M shares of common stockAugust 15, 2025 | msn.comSynergy Chc EPS Jumps 86 Percent in Q2August 15, 2025 | theglobeandmail.comSynergy CHC Corp.: Synergy CHC Corp Reports Second Quarter 2025 Financial Results and its Tenth Consecutive Quarter of ProfitabilityAugust 14, 2025 | finanznachrichten.deSynergy CHC reports Q2 EPS 17c vs 9c last yearAugust 14, 2025 | msn.comSynergy CHC Corp. Reports Strong Second Quarter 2025 Financial Results with Significant Year-over-Year GrowthAugust 14, 2025 | quiverquant.comQSynergy CHC Corp Reports Second Quarter 2025 Financial Results and its Tenth Consecutive Quarter of ProfitabilityAugust 14, 2025 | globenewswire.comHead-To-Head Contrast: Synergy CHC (NASDAQ:SNYR) vs. Krispy Kreme (NASDAQ:DNUT)August 10, 2025 | americanbankingnews.comNew to The Street TV Commercial Campaigns Achieve Millions of Views with 87% Average Completion RateAugust 5, 2025 | indystar.comINew to The Street Launches 1,000+ Commercial TV Blitz for Synergy CHC ($SNYR), Makers of Focus Factor(R) – Adds NewsOut Video PR Coverage & NYC #1 Market SaturationAugust 5, 2025 | desmoinesregister.comDJack Ross Buys Handful Of Shares In Synergy CHCAugust 3, 2025 | finance.yahoo.comInsider Buying: Synergy CHC Corp. (NASDAQ:SNYR) CEO Purchases 3,750 Shares of StockAugust 1, 2025 | insidertrades.comSynergy CHC Corp. Announces Second Quarter 2025 Earnings and Conference Call InformationJuly 31, 2025 | manilatimes.netMSynergy CHC Corp. Stock (SNYR) Opinions on Retail Distribution ExpansionJuly 31, 2025 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMYNZ, SNYR, MURA, and MAAQ Company DescriptionsMana Capital Acquisition NASDAQ:MAAQ$3.50 -0.17 (-4.63%) As of 08/20/2025Mana Capital Acquisition Corp. focuses on engaging in a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It intends to focus on businesses operating in the healthcare, technology, green economy, and consumer products sectors in North America, Europe, and Asia. The company was incorporated in 2021 and is based in Dover, Delaware.Mural Oncology NASDAQ:MURA$2.07 -0.02 (-0.96%) Closing price 04:00 PM EasternExtended Trading$2.08 +0.01 (+0.24%) As of 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.Mainz Biomed NASDAQ:MYNZ$1.76 +0.04 (+2.33%) Closing price 04:00 PM EasternExtended Trading$1.74 -0.01 (-0.85%) As of 05:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.Synergy CHC NASDAQ:SNYR$2.90 +0.04 (+1.40%) As of 03:59 PM EasternSynergy CHC Corp. engages in the marketing and distribution of branded health and wellness products. The company was founded on December 29, 2010 and is headquartered in Westbrook, ME. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Robotics Stocks at the Heart of the Robotics Revolution Analog Devices and an AI-Driven Semiconductor Supercycle Palantir is Selling Off, BigBear.ai Could Be Your Hedge ASML Has Entered Buy Territory, But Only For Patient Investors Lowe’s Builds Value for Investors: Still a Good Buy in 2025 Target: Missing the Mark in 2025—Downtrend May Continue Toll Brothers: A Great Buy and Hold Stock With Risks in 2025 Amazon Stock Sets Up for Breakout After Bullish Crossover Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access